The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! About 967,210 shares traded hands. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 14.11% since March 9, 2016 and is uptrending. It has outperformed by 6.69% the S&P500.
The move comes after 6 months negative chart setup for the $524.22 million company. It was reported on Oct, 12 by Barchart.com. We have $4.81 PT which if reached, will make NASDAQ:KERX worth $26.21 million less.
Analysts await Keryx Biopharmaceuticals (NASDAQ:KERX) to report earnings on November, 3. They expect $-0.22 EPS, up 24.14% or $0.07 from last year’s $-0.29 per share. After $-0.42 actual EPS reported by Keryx Biopharmaceuticals for the previous quarter, Wall Street now forecasts -47.62% EPS growth.
Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage
Out of 14 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 43% are positive. Keryx Biopharmaceuticals has been the topic of 28 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was downgraded by TH Capital on Monday, August 10 to “Buy”. The company was downgraded on Monday, August 10 by Roth Capital. The stock has “Sell” rating given by BTIG Research on Thursday, August 6. The firm earned “Market Perform” rating on Wednesday, September 9 by Raymond James. The firm has “Buy” rating given on Thursday, August 6 by Maxim Group. As per Tuesday, August 2, the company rating was downgraded by Stifel Nicolaus. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Sell” rating given on Friday, August 28 by Zacks. The firm has “Market Perform” rating by FBR Capital given on Tuesday, August 2. The firm earned “Sell” rating on Thursday, September 3 by Citigroup. As per Tuesday, March 29, the company rating was maintained by Maxim Group.
According to Zacks Investment Research, “Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.”
Insitutional Activity: The institutional sentiment decreased to 0.49 in Q2 2016. Its down 1.00, from 1.49 in 2016Q1. The ratio dropped, as 29 funds sold all Keryx Biopharmaceuticals shares owned while 43 reduced positions. 12 funds bought stakes while 23 increased positions. They now own 64.01 million shares or 1.49% less from 64.98 million shares in 2016Q1.
Art Advsrs Limited Liability Company has 0.02% invested in the company for 71,254 shares. Wells Fargo And Com Mn accumulated 0% or 39,782 shares. Sei Invests Co last reported 0% of its portfolio in the stock. Millennium Mngmt Ltd Liability Co reported 970,804 shares or 0.01% of all its holdings. The California-based California State Teachers Retirement Systems has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Old West Inv Mngmt Limited Com holds 0.61% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 126,230 shares. Alpine Vi Ltd Llc accumulated 0.05% or 16,554 shares. Janney Montgomery Scott Lc has 0.01% invested in the company for 84,209 shares. Woodstock Corporation has 0.08% invested in the company for 56,593 shares. Rhenman And Asset Mgmt, a Sweden-based fund reported 450,111 shares. The United Kingdom-based Legal & General Group Inc Public Ltd has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Parametric Assoc Lc has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Great West Life Assurance Co Can owns 10,000 shares or 0% of their US portfolio. Cam Group A S holds 0.05% or 421,110 shares in its portfolio. Alliancebernstein L P has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX).
Insider Transactions: Since April 15, 2016, the stock had 0 insider buys, and 9 sales for $107,594 net activity. $5,353 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) was sold by Adams Brian on Friday, April 15. Neylan John F. sold 1,217 shares worth $9,042. Madison Greg had sold 917 shares worth $4,933 on Wednesday, October 5. Holmes Scott A also sold $36,322 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) on Friday, July 29.
More recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: Finance.Yahoo.com which released: “KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a …” on September 27, 2016. Also Marketwatch.com published the news titled: “Keryx Biopharmaceuticals says kidney disease drug won’t be available until the …” on August 01, 2016. Seekingalpha.com‘s news article titled: “Keryx Biopharmaceuticals Is Likely To Fully Recover From August” with publication date: October 03, 2016 was also an interesting one.
KERX Company Profile
Keryx Biopharmaceuticals, Inc., incorporated on October 22, 1998, is a biopharmaceutical company. The Firm is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Firm operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.